COMMUNIQUÉS West-GlobeNewswire

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®

03/10/2018 - 15:00

52-week analysis highlights the potential for seladelpar to offer patients improved efficacy and better tolerability than existing second line treatment Third consecutive year data from the development of seladelpar in [...]

JSC Olainfarm holds Second Quarter 2018 Investor Conference Webinar

03/10/2018 - 14:49

Olainfarm holds Second Quarter 2018 Investor Conference Webinar JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on [...]

Scythian Biosciences Appoints Brady Cobb as CEO

03/10/2018 - 14:41

Company Also Names Andy DeFrancesco Chief Investment Officer TORONTO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) [...]

Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207

03/10/2018 - 14:30

FREMONT, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver [...]

VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

03/10/2018 - 14:30

Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain Second FDA Fast Track designation for AV-101 since December 2017 marks another milestone for VistaGen's R [...]

Aleafia Announces Options Grant

03/10/2018 - 14:20

TORONTO, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia “) or (the “ Company “), one of Canada’s leading, vertically integrated cannabis companies, is announcing [...]

Nexstim Plc Launches Presence in Asia with Distribution Agreement of its SmartFocus(TM) TMS system to Access Hong Kong Market

03/10/2018 - 14:01

Nexstim Plc Launches Presence in Asia with Distribution Agreement of its SmartFocus(TM) TMS system to Access Hong Kong Market First NBT ® system for applications in depression already installed in Hong Kong Press [...]

Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018

03/10/2018 - 14:01

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial agents to address multi- [...]

Sanford Health Announces Adoption of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment

03/10/2018 - 14:00

Medical facility becomes first in South Dakota to offer intraoperative radiation therapy with the revolutionary Xoft System to improve patient care NASHUA, N.H. and SIOUX FALLS, S.D., Oct. 03, 2018 (GLOBE NEWSWIRE) -- [...]

Forty Seven Inc. Appoints Leading Experts in Immuno-Oncology to its Scientific Advisory Board (SAB)

03/10/2018 - 14:00

MENLO PARK, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV) today announced the formation of its Scientific Advisory Board (SAB), comprised of four leading scientists in the fields of [...]

Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.

03/10/2018 - 14:00

EDISON, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of [...]

Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018

03/10/2018 - 14:00

WALTHAM, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced [...]

CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol® Cyclo™ administered intravenously in Niemann Pick Disease Type C (NPC)

03/10/2018 - 14:00

ALACHUA, Fla., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced initial [...]

Altimmune Closes on $16.9 Million in Funding

03/10/2018 - 14:00

$12 million underwritten public offering closed October 2 $4.9 million registered direct offering closed September 26 GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage [...]

Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection

03/10/2018 - 13:52

TYMLOS is now covered for 64% of Medicare Part D insured lives WALTHAM, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is [...]

Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers

03/10/2018 - 13:47

Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: [...]

Results from a large observational study combining the National Early Warning Score (NEWS) with suPAR documents that suPARnostic® improves risk stratification in acute medical patients

03/10/2018 - 13:45

Press Release Birkerød, 3 October 2018 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that data from a study [...]

Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)

03/10/2018 - 13:30

CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to [...]

Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors

03/10/2018 - 13:30

SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]